Neuroleptic malignant syndrome following combination of sertraline and paroxetine: A case report

General Hospital Psychiatry

Volumn 35, Issue 3, 2013, Pages 327.e7-327.e8

  Uguz, Faruk ^a   Sonmez, Erdem Önder ^a  

^a NECMETTIN ERBAKAN UNIVERSITY   (Turkey)

Author keywords

Antidepressants; Neuroleptic malignant syndrome; Paroxetine; Sertraline

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BROMOCRIPTINE; CREATINE KINASE; CREATININE; LORAZEPAM; PAROXETINE; SERTRALINE; UREA;

ADULT; ANHEDONIA; ANOREXIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONSULTATION; DEPRESSION; DRUG WITHDRAWAL; DSM-IV; EATING DISORDER; FEMALE; FEVER; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INSOMNIA; LABORATORY TEST; LEUKOCYTE COUNT; MENTAL DEFICIENCY; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; MUTISM; NEUROLEPTIC MALIGNANT SYNDROME; PSYCHOSOCIAL DISORDER; UREA BLOOD LEVEL;

EID: 84876999247     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2012.11.004     Document Type: Article

References (17)

1. Strawn J.R., Keck P.E., Caroff S.N. Neuroleptic malignant syndrome. Am J Psychiatry 2007, 164:870-876.
2. Gillman P.K. Neuroleptic malignant syndrome: mechanisms, interactions, and causality. Mov Disord 2010, 25:1780-1790.
3. Anglin R.E., Rosebush P.I., Mazurek M.F. Neuroleptic malignant syndrome: a neuroimmunologic hypothesis. CMAJ 2010, 182:E834-E838.
4. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Press, Washington, DC. Fourth Edition.
5. Tanii H., Ichihashi K., Inoue K., Fujita K., Okazaki Y. Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1176-1178.
6. Miranda M., Soto F., Fischman P. Forme fruste of neuroleptic malignant syndrome associated with the use of sertraline. Parkinsonism Relat Disord 2011, 17:217-218.
7. Lu T.C., Chu P.L., Wu C.S., Tsai K.C., Chen W.J. Neuroleptic malignant syndrome after the use of venlafaxine in a patient with generalized anxiety disorder. J Formos Med Assoc 2006, 105:90-93.
8. Edokpolo O, Fyyaz M. Lithium toxicity and neurologic effects: probable neuroleptic malignant syndrome resulting from lithium toxicity. Case Rep Psychiatry (in Press).
9. Stevens D.L. Association between selective serotonin reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother 2008, 42:1290-1297.
10. Kontaxakis V.P., Havaki-Kontaxaki B.J., Pappa D.A., Katritsis D.E., Christodoulou G.N. Neuroleptic malignant syndrome after addition to paroxetine to olanzapine. J Clin Psychopharmacol 2003, 23:671-672.
11. Matsumoto R., Kitabayashi Y., Nakatomi Y., Tsuchida H., Fukui K. Neuroleptic malignant syndrome induced by quetiapine and fluvoxamine. Am J Psychiatry 2005, 162:812.
12. Sternback H. The serotonin syndrome. Am J Psychiatry 1991, 148:705-713.
13. Kim J.M., Lee S.T., Song E.C., Jung K.H., Sinn D.I., Chung H., et al. Neurotoxic syndrome developed after taking sertraline and risperidone. J Clin Neurol 2007, 3:165-167.
14. Reeves R.R., Mack J.E., Beddingfield J.J. Neurotoxic syndrome associated with risperidone and fluvoxamine. Ann Pharmacother 2002, 36:44043.
15. Perry P.J., Wilborn C.A. Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. Ann Clin Psychiatry 2012, 24:155-162.
16. Caley C.F. Extrapyramidal reactions and the selective serotonin reuptake inhibitors. Ann Pharmacother 1997, 31:1481-1489.
17. Preskorn S.H. Treatment options for the patient who does not respond well to initial antidepressant therapy. J Psychiatr Pract 2009, 15:202-210.